Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Celon Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 179.95%.
The historical rank and industry rank for Celon Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0RKX'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.03 Med: -1.57 Max: 46.5
Current: 46.5
During the past 11 years, Celon Pharma's highest ROC (Joel Greenblatt) % was 46.50%. The lowest was -11.03%. And the median was -1.57%.
LTS:0RKX's ROC (Joel Greenblatt) % is ranked better than 83.49% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.53
vs LTS:0RKX: 46.50
Celon Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Celon Pharma ROC (Joel Greenblatt) % Related Terms
Celon Pharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Celon Pharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKX vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 179.95% mean?
Celon Pharma (LTS:0RKX) has a ROC (Joel Greenblatt) % of 179.95% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #162 out of 981 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Celon Pharma's ROC (Joel Greenblatt) % too high?
Celon Pharma's current ROC (Joel Greenblatt) % is 179.95%. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.53. Celon Pharma's value of 179.95% is 1460.7% above this industry median. Based on the distribution chart, Celon Pharma ranks #162 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #162 out of 981 companies for ROC (Joel Greenblatt) %. This places Celon Pharma in the top 17% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.53. Celon Pharma's value of 179.95% is 1460.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.53, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current ROC (Joel Greenblatt) % of 179.95% is 1460.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current ROC (Joel Greenblatt) % is 179.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current ROC (Joel Greenblatt) % of 179.95%. The stock's GF Value™ is zł25.29, compared to a current price of zł22.50 — trading 11% below its estimated fair value. The current ROC (Joel Greenblatt) % is 179.95% and 1460.7% above the Drug Manufacturers industry median of 11.53. Celon Pharma's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current ROC (Joel Greenblatt) % is 179.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (LTS:0RKX) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł22.50 is trading 11% below its estimated GF Value™ of zł25.29.
Key valuation signals for LTS:0RKX:
ROC (Joel Greenblatt) %: 179.95%
GF Value™: zł25.29 vs. price of zł22.50 (11% below fair value)
Industry Position: 1460.7% above the Drug Manufacturers median (#162 of 981)
No single metric tells the full story. See the LTS:0RKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
44GF Score
Get the complete analysis for LTS:0RKX
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
